NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Their core work

NICE is the UK's authority on clinical and cost-effectiveness guidance, setting the standards for which treatments, diagnostics, and interventions the NHS adopts. In H2020 projects, NICE contributes its deep expertise in Health Technology Assessment (HTA), health economics, real-world evidence evaluation, and data standardisation. Their role is to ensure that research outputs are assessed through the lens of clinical value, cost-effectiveness, and implementability in public healthcare systems. They bridge the gap between clinical research and actual adoption by health systems.

What they specialise in

How they've shifted over time

In 2015–2018, NICE's H2020 work centred on traditional HTA reform — adaptive regulatory pathways (ADAPT-SMART), real-world evidence for Alzheimer's (ROADMAP), and improving R&D decision models. From 2018 onward, their focus shifted decisively toward health data infrastructure: federated data networks, OMOP/OHDSI standardisation (EHDEN), machine learning for personalised treatment (HTx), and digital health outcomes (HARMONY PLUS). This mirrors a broader institutional move from evaluating finished technologies to shaping how health data ecosystems are built so that evidence generation is embedded from the start.

NICE is moving upstream — from assessing technologies after development to embedding evidence standards and data interoperability into the research process itself, making them a valuable partner for any project needing HTA-ready data architectures.

How they like to work

NICE participates exclusively as a partner — zero coordinator roles across all 13 projects — which reflects their position as a domain authority contributing specialised input rather than managing large consortia. With 223 unique partners across 26 countries, they operate as a highly connected hub in European health research. Their consistent presence in IMI (Innovative Medicines Initiative) projects shows they are trusted by both public and private sectors, making them an accessible and well-networked partner to bring into a consortium.

NICE has collaborated with 223 distinct partners across 26 countries, giving them one of the broadest networks among UK public health bodies in H2020. Their partnerships span academic hospitals, pharmaceutical companies (via IMI), regulatory agencies, and health data organisations across Western and Southern Europe.

What sets them apart

NICE is not a research lab — it is the institution that decides what gets adopted by one of Europe's largest public health systems. Having NICE in a consortium signals that the project's outputs are being designed with real-world implementation and reimbursement decisions in mind. For any health innovation project, NICE's involvement adds immediate credibility with regulators, payers, and health system decision-makers across Europe.

Highlights from their portfolio

• HTx
  Largest single grant (EUR 839,398) and their flagship project on next-generation HTA methods including AI, real-world data synthesis, and personalised treatment assessment.
• EHDEN
  Major European health data infrastructure project (EUR 610,000 to NICE) building a federated network using OMOP CDM and FAIR principles — represents their strategic shift toward data standardisation.
• HARMONY
  Long-running IMI project (2017–2023) creating a big data platform for blood cancers, demonstrating NICE's capacity to contribute to large-scale, multi-year data initiatives in oncology.